Hemoglobin News and Research

RSS

Low levels of oxygen, nitric oxide appear to have unfortunate synergy for patients with sickle cell disease

Low levels of both oxygen and the powerful blood vessel dilator nitric oxide appear to have an unfortunate synergy for patients with sickle cell disease, researchers report.

21 Mar 2014

Aetna honored with 2014 Innovation in Reducing Health Care Disparities Award

Aetna was honored today by the National Business Group on Health (NBGH) with the 2014 Innovation in Reducing Health Care Disparities Award. Aetna is a three-time recipient of the award that recognizes organizations for their commitment to equality in health care and exceptional support for cultural diversity.

8 Mar 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

ADA screening guidelines may lead to missed diagnoses of type 2 diabetes in children, says study

New American Diabetes Association (ADA) screening guidelines may lead to the missed diagnoses of type 2 diabetes in children, according to a new study by University of Michigan.

12 Feb 2014

AstraZeneca HealthCare Foundation to award grants to 19 organizations to improve cardiovascular health

The AstraZeneca HealthCare Foundation's Connections for Cardiovascular Health program today announced it will award nearly $3.7 million in grants to 19 nonprofit organizations dedicated to improving cardiovascular health in local communities.

11 Feb 2014

Analysis on long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma

An EORTC analysis appearing in Annals of Oncology confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. Additionally, hemoglobin at baseline was found to be a new prognostic factor.

11 Feb 2014

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.

5 Feb 2014

Blood pressure lowering linked with reduced risk for cognitive decline in patients with T2DM

Intensive blood pressure and cholesterol lowering was not associated with reduced risk for diabetes-related cognitive decline in older patients with long-standing type 2 diabetes mellitus, according to a study by Jeff D. Williamson, M.D., M.H.S., of the Wake Forest School of Medicine, Winston-Salem, N.C., and colleagues.

4 Feb 2014

Trinidad and Tobago, Johns Hopkins Medicine celebrate achievements of Diabetes Outreach Program

Members of the Trinidad and Tobago Health Science Initiative’s Diabetes Outreach Program joined the country’s Minister of Health Fuad Khan Tuesday in Port of Spain to celebrate the program’s achievements in fighting diabetes in Trinidad and Tobago.

30 Jan 2014

CCSC identifies 5 routine practices for multidisciplinary teams of critical care professionals

The American Association of Critical-Care Nurses (AACN) — as part of the Critical Care Societies Collaborative (CCSC) — has identified five routine critical care practices that should be questioned because they may not always be necessary and could, in fact, be harmful.

29 Jan 2014

Researchers discover simple blood test that can predict diabetes risk much earlier

An estimated 25.8 million Americans have diabetes. Another 79 million are thought to have "prediabetes," meaning they are at risk of developing type-2 diabetes.

28 Jan 2014

Research findings provide insights into risks associated with isolated mild hyperglycemia

Despite having mild hyperglycemia for approximately 50 years, patients with a mutation in the gene encoding the enzyme glucokinase had a low prevalence of clinically significant vascular complications, findings that provide insights into the risks associated with isolated mild hyperglycemia, according to a study in the January 15 issue of JAMA.

15 Jan 2014

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec and Sangamo BioSciences, Inc. announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin.

9 Jan 2014

NeoGenomics launches new test for detection of mutations in CALR gene

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a new test for the detection of mutations in the calreticulin (CALR) gene. The CALR gene is a novel biomarker that was reported to be specific for myeloproliferative neoplasms (MPN) for the first time at the annual meeting of the American Society of Hematology last month.

8 Jan 2014

Researchers receive Doris Duke Foundation award to predict sickle cell crisis, monitor treatments

Researchers at Case Western Reserve University have received a $486,000 Doris Duke Foundation award to discover how to predict when sickle cell disease patients will suffer an acute crisis and monitor the effectiveness of treatments.

20 Dec 2013

Nonsurgical treatment of periodontal disease does not improve glycemic control in patients with diabetes

A recent study published in the Journal of the American Medical Association (JAMA) found that nonsurgical treatment of periodontal disease does not improve glycemic control in patients with type 2 diabetes.

18 Dec 2013

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes.

16 Dec 2013

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

A range of studies highlighting late-breaking research advances in the understanding and treatment of blood cancers and bleeding disorders are being presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans.

12 Dec 2013

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.